The Law Offices of Frank R. Cruz Announces Investigation of Precigen, Inc. (PGEN) on Behalf of InvestorsBusiness Wire • 10/02/20
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Precigen, Inc. f/k/a Intrexon Corporation – PGEN, XONBusiness Wire • 10/02/20
Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-associated CancersPRNewsWire • 08/17/20
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 DiabetesPRNewsWire • 08/10/20
Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart FailurePRNewsWire • 08/06/20
Precigen to Announce Second Quarter and First Half 2020 Financial Results on August 10thPRNewsWire • 08/03/20
Precigen to Participate in Upcoming JMP Securities Hematology and Oncology ForumPRNewsWire • 06/11/20
Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of ShareholdersPRNewsWire • 06/04/20
8 Stocks That Could Double From 2020 to 2021, With No COVID-19 Focus at All24/7 Wall Street • 05/29/20
Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20